Velaglucerase alfa as a therapeutic option for Gaucher disease

References

• Harmanci O, Bayraktar Y. Gaucher disease: new developments in treatment and etiology. World J. Gastroenterol.14(25), 3968–3973 (2008).
   PubMedGoogle Scholar
• Boven LA, van Meurs M, Boot RG et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol.122(3), 359–369 (2004).
   PubMed Web of Science ®Google Scholar
• Bultron G, Kacena K, Pearson D et al. The risk of Parkinson’s disease in type 1 Gaucher disease. J. Inherit. Metab. Dis.33(2), 167–173 (2010).
   PubMed Web of Science ®Google Scholar
• Lo SM, Stein P, Mullaly S et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types – correlation with genotype and phenotype. Am. J. Hematol.85(5), 340 (2010).
   PubMedGoogle Scholar
• Grewal RP, Doppelt SH, Thompson MA et al. Neurologic complications of nonneuronopathic Gaucher’s disease. Arch. Neurol.48(12), 1271–1272 (1991).
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl J. Med.324(21), 1464–1470 (1991).
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med.122(1), 33–39 (1995).
   PubMed Web of Science ®Google Scholar
• Sims KB, Pastores GM, Weinreb NJ et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin. Genet.73(5), 430–440 (2008).
   PubMed Web of Science ®Google Scholar
• Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol. Genet. Metab.90(2), 157–163 (2007).
   PubMed Web of Science ®Google Scholar
• Vellodi A, Tylki-Szymanska A, Davies EH et al. European Working Group on Gaucher Disease. Management of neuronopathic Gaucher disease: revised recommendations. J. Inherit. Metab. Dis.32(5), 660–664 (2009).
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE et al. Prevalence of lysosomal storage disorders. JAMA281(3), 249–254 (1999).
   PubMed Web of Science ®Google Scholar
• Somaraju UR, Tadepalli K. Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Database Syst. Rev. (4), CD006974 (2008).
   Google Scholar
• Pastores GM, Giraldo P, Chérin P et al. Goal-oriented therapy with miglustat in Gaucher disease. Curr. Med. Res. Opin25(1), 23–37 (2009).
   PubMed Web of Science ®Google Scholar
• Zimran A, Loveday K, Fratazzi C et al. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells Mol. Dis.39, 115–118 (2007).
   PubMed Web of Science ®Google Scholar
• Pastores GM. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs24(1), 41–47 (2010).
   PubMedGoogle Scholar
• Shaaltiel Y, Bartfeld D, Hashmueli S et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol. J.5(5), 579–590 (2007).
   PubMed Web of Science ®Google Scholar
• Elbein AD, Tropea JE, Mitchell M et al. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J. Biol. Chem.265, 15599–15605 (1990).
   PubMed Web of Science ®Google Scholar
• Brumshtein B, Salinas P, Peterson B et al. Characterization of gene-activated human acid-b-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology20(1), 24–32 (2010).
   PubMed Web of Science ®Google Scholar
• Xu YH, Sun Y, Barnes S, Grabowski GA. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One5(5), e10750 (2010).
   Google Scholar
• Zimran A, Altarescu G, Philips M et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood115(23), 4651–4656 (2010).
   PubMed Web of Science ®Google Scholar
• Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol.41(4 Suppl. 5), 4–14 (2004).
   PubMed Web of Science ®Google Scholar
• Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol. Dis. DOI: 10.1016/j.bcmd.2010.07.008. (2010) (Epub ahead of print).
   Google Scholar
• Elstein D, Foldes AJ, Zahrieh D et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Presented at: 9th International European Working Group on Gaucher Disease. Cologne, Germany, 30 June–3 July 2010.
   Google Scholar
• Gonzalez DE, Ben Dridi MF, Lukina EA et al. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: results from a randomized, double-blind Phase III study. Presented at: 9th International European Working Group on Gaucher Disease. Cologne, Germany, 30 June–3 July 2010.
   Google Scholar
• Zimran A, Gonzalez D, Crombez E et al. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease. Presented at: Lysosomal Disease Network 6th WORLD Symposium. Miami, FL, USA, 10–12 February 2010.
   Google Scholar
• Ruiz J, Barzegar S, Clarke A et al. Antigenic differences in patients receiving velaglucerase alfa or imiglucerase treatment. Presented at: 9th International European Working Group on Gaucher Disease. Cologne, Germany, 30 June–3 July 2010.
   Google Scholar
• Starzyk K, Richards S, Yee J et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet. Metab.90(2), 157–163 (2007).
   PubMed Web of Science ®Google Scholar
• Chung Y, Park H, Han S et al. Imiglucerase biosimialr development for Gaucher disease. Presented at: 9th International European Working Group on Gaucher Disease. Cologne, Germany, 30 June–3 July 2010.
   Google Scholar
• Lukina E, Watman N, Arreguin EA et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood116(6), 893–899 (2010).
   PubMed Web of Science ®Google Scholar
• Elstein D, Abrahamov A, Hadas-Halpern I et al. Withdrawal of enzyme replacement therapy in Gaucher’s disease. Br. J. Haematol.110(2), 488–492 (2000).
   PubMed Web of Science ®Google Scholar
• Goldblatt J, Fletcher JM, McGill J et al. Enzyme replacement therapy ‘drug holiday’: results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol. Dis. DOI: 10.1016/j.bcmd.2010.05.002 2010 (2010) (Epub ahead of print).
   PubMedGoogle Scholar